CTNM (Contineum Therapeutics) Accounts Payable & Accrued Expense : $1.85 Mil (As of Jun. 2024)

View and export this data going back to 2024. Start your Free Trial

What is Contineum Therapeutics Accounts Payable & Accrued Expense?

Contineum Therapeutics's quarterly accounts payable & accrued expense increased from Dec. 2023 ($3.12 Mil) to Mar. 2024 ($4.80 Mil) but then declined from Mar. 2024 ($4.80 Mil) to Jun. 2024 ($1.85 Mil).

Contineum Therapeutics's annual accounts payable & accrued expense declined from Dec. 2021 ($1.42 Mil) to Dec. 2022 ($1.18 Mil) but then increased from Dec. 2022 ($1.18 Mil) to Dec. 2023 ($3.12 Mil).

Contineum Therapeutics Accounts Payable & Accrued Expense Historical Data

The historical data trend for Contineum Therapeutics's Accounts Payable & Accrued Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Contineum Therapeutics Accounts Payable & Accrued Expense Chart

Contineum Therapeutics Annual Data

Trend

Dec21

Dec22

Dec23

Accounts Payable & Accrued Expense

1.42

1.18

3.12

Contineum Therapeutics Quarterly Data
	Dec21	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24
Accounts Payable & Accrued Expense	Get a 7-Day Free Trial				-	4.82	3.12	4.80	1.85

Contineum Therapeutics Accounts Payable & Accrued Expense Calculation

Accounts payable & accrued expense usually includes accounts payable, accrued compensation and related benefits, etc.

Accounts payable is money owed by a business to its suppliers shown as a liability on a company's balance sheet. It is distinct from notes payable liabilities, which are debts created by formal legal instrument documents.

It is part of the current portion of the liabilities (due within one year or within the normal operating cycle if longer) reflected on the balace sheet of the company. A higher Accounts Payable means lower Working Capital needed to operate the business.

Contineum Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Contineum Therapeutics Inc (NAS:CTNM) » Definitions » Accounts Payable & Accrued Expense

Comparable Companies

Traded in Other Exchanges

N/A

Address

10578 Science Center Drive, Suite 200, San Diego, CA, USA, 92121

Website

https://www.contineum-tx.com

Contineum Therapeutics Inc is a clinical stage biopharmaceutical company focused on discovering and developing novel, oral small molecule therapies for NI&I indications with high unmet need. Its internally-discovered drug candidates, PIPE-791 and PIPE-307, PIPE-791, is a novel, brain penetrant, small molecule inhibitor of the LPA1R in development for IPF and PIPE-307, is a novel, small molecule selective inhibitor of the muscarinic type 1 M1R, in development for depression and RRMS.

Contineum Therapeutics Headlines

From GuruFocus

Contineum Therapeutics Announces Pricing of Initial Public Offering

By GlobeNewswire • 04-05-2024